Rationale and design of the ULYSS trial: A randomized multicenter evaluation of the efficacy of early Impella CP implantation in acute coronary syndrome complicated by cardiogenic shock - 11/10/23
, Marc Laine, MD, MSc d, Guillaume Schurtz, MD, MSc e, Francois Roubille, MD, PhD f, Pierre Coste, MD, PhD g, Guillaume Leurent, MD, MSc, h, Sami Hraiech, MD i, Mathieu Pankert, MD j, Quaino Gonzalo, MD k, Thibaut Dabry, MD l, Vincent Letocart, MD m, Sandrine Loubière, PhD n, o, Noémie Resseguier, MD, PhD n, o, Laurent Bonello, MD, PhD dRésumé |
Context |
Despite 20 years of improvement in acute coronary syndromes care, patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) remains a major clinical challenge with a stable incidence and mortality. While intra-aortic balloon pump (IABP) did not meet its expectations, percutaneous mechanical circulatory supports (pMCS) with higher hemodynamic support, large availability and quick implementation may improve AMICS prognosis by enabling early hemodynamic stabilization and unloading. Both interventional and observational studies suggested a clinical benefit in selected patients of the IMPELLAⓇ CP device within in a well-defined therapeutic strategy. While promising, these preliminary results are challenged by others suggesting a higher rate of complications and possible poorer outcome. Given these conflicting data and its high cost, a randomized clinical trial is warranted to delineate the benefits and risks of this new therapeutic strategy.
Design |
The ULYSS trial is a prospective randomized open label, 2 parallel multicenter clinical trial that plans to enroll patients with AMICS for whom an emergent percutaneous coronary intervention (PCI) is intended. Patients will be randomized to an experimental therapeutic strategy with pre-PCI implantation of an IMPELLAⓇ CP device on top of standard medical therapy or to a control group undergoing PCI and standard medical therapy. The primary objective of this study is to compare the efficacy of this experimental strategy by a composite end point of death, need to escalate to ECMO, long-term left ventricular assist device or heart transplantation at 1 month. Among secondary objectives 1-year efficacy, safety and cost effectiveness will be assessed.
Clinical Trial Registration |
NCT05366452
Le texte complet de cet article est disponible en PDF.Abbreviations : ACS, AMI, AMICS, BNP, CI, NtproBNP, CS, ECMO, IABP, ICU, LVAD, MCS, pMCS, PCI, QALY, SBP, RHC, ROSC, SCAI, ScVO2
Plan
Vol 265
P. 203-212 - novembre 2023 Retour au numéro
Article précédent
- Rationale and design of the pullback pressure gradient (PPG) global registry
- Daniel Munhoz, Carlos Collet, Takuya Mizukami, Andy Yong, Antonio Maria Leone, Ashkan Eftekhari, Brian Ko, Bruno R. da Costa, Colin Berry, Damien Collison, Divaka Perera, Evald Høj Christiansen, Fernando Rivero, Frederik M. Zimmermann, Hirohiko Ando, Hitoshi Matsuo, Masafumi Nakayama, Javier Escaned, Jeroen Sonck, Koshiro Sakai, Julien Adjedj, Liyew Desta, Lokien X. van Nunen, Nick E.J. West, Stephane Fournier, Tatyana Storozhenko, Tetsuya Amano, Thomas Engstrøm, Thomas Johnson, Toshiro Shinke, Simone Biscaglia, William F. Fearon, Ziad Ali, Bernard De Bruyne, Nils P. Johnson
- The coronary microvascular angina cardiovascular magnetic resonance imaging trial: Rationale and design
- Conor P. Bradley, Vanessa Orchard, Gemma McKinley, Robert Heggie, Olivia Wu, Richard Good, Stuart Watkins, Mitchell Lindsay, Hany Eteiba, James McGowan, Ross McGeoch, David Corcoran, Peter Kellman, Alex McConnachie, Colin Berry
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?